Continued profitability and revenue growth for Bactiguard
Continued profitability and revenue growth for Bactiguard
First quarter 2025 (January – March)
- Total revenue amounted to SEK 62.7 (58.8) million, an increase of SEK 3.9 million corresponding to 6.7%.
- Net sales amounted to SEK 59.1 (53.9) million, an increase of SEK 5.1 million corresponding to 9.5%. Adjusted for currency effects of SEK 1.7 million, net sales increased by 6.3%.
- Operating loss amounted to SEK 2.6 (12.9) million.
- EBITDA amounted to SEK 9.4 (-1.5) million.
- Net loss for the period amounted to SEK 4.7 (9.9) million.
- Loss per share, before and after dilution, amounted to SEK 0.13 (0.28).
- Cash flow from operating activities amounted to SEK -12.1 (-19.1) million corresponding to SEK -0.35 (-0.54)
Christine Lind, CEO of Bactiguard comments:
“Following the 2024 financial turnaround, we continue our profitable path with yet another strong quarter. EBITDA amounted to SEK 9.4 million (Q1 2024: SEK -1.5 million) and revenues increased by 6.7 percent compared to Q1 last year and landed at SEK 62.7 million (Q1 2024: SEK 58.8 million). Our license business developed well, primarily driven by the successful collaboration with license partner BD, demonstrating a consistent positive financial performance thanks to our strategic transition. The Wound Management portfolio also had a strong quarter with a revenue increase of more than 50 percent, fueled by a significant rise in sales of Hydrocyn aqua. During the quarter, we also updated our strategic and financial targets and core therapeutic areas, areas where our infection prevention solutions can play an important role in addressing the unmet need associated with medical device related infections.”
Bactiguard Holding AB’s (publ) report for the first quarter 2025 is available at https://ir.bactiguard.com/
This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, 2025-04-24 at 07:00 CET.
For further information, please contact:
Patrick Bach, CFO +46 761 295 911
Nina Nornholm, Head of Communications & Investor Relations +46 708 550 356
To participate in the audiocast, please use this link: https://ir.bactiguard.com/report/q1-2025/
To participate only by conference call, please register on the link above. Questions can be asked either in writing via the audiocast or orally if you attend the conference call.
For further information, please contact:
Patrick Bach, CFO +46 761 295 911
Nina Nornholm, Head of Communications & Investor Relations +46 708 550 356
To participate in the audiocast, please use this link: https://ir.bactiguard.com/report/q1-2025/
To participate only by conference call, please register on the link above. Questions can be asked either in writing via the audiocast or orally if you attend the conference call.
